The thought on everyone's mind when looking at Amarin (AMRN 2.43%) as an investor right now is: What approach is the company going to take in commercializing its new hypertriglyceridemia drug, Vascepa? Many people consider the company a potential acquisition target; others thought it would seek a partnership before going forward. But after the release of yesterday's conference call, the evidence might suggest that it plans to commercialize Vascepa on its own, an option that previously had some investors a little apprehensive. Motley Fool health care analyst Max Macaluso talks in this video about his take on Amarin's strategy going forward and why the CEO's words were well-received by the market.
Could Amarin Reject a Buyout?
By Max Macaluso and Brenton Flynn – Nov 9, 2012 at 12:34PM
NASDAQ: AMRN
Amarin Plc
Market Cap
$400M
Today's Change
(-2.43%) $0.48
Current Price
$19.24
Price as of October 27, 2025 at 4:00 PM ET
What did the market think about Amarin's Q3 update?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo